Hemepath Lymph Node Intro Lecture Flashcards

1
Q

Normal lymph node architecture

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Germinal center response to antigen

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
A

Toxoplasma lymphadenitis

Notice the epithelioid histiocytes present in sparse aggregates and infiltrating into the germinal centers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Findings of florid follicular hyperplasia, intrafollicular plasma cells, and increased paracortical plasma cells should make you suspiciuos for. . .

A

Syphilis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Typical look of parafollicular hyperplasia

A

The small lymphocytes are mostly T cells and the larger, evenly spaced cells are interdigitating dendritic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Paracortical lymphoid hyperplasia is common in. . .

A

dermatopathic lymphadenitis

viral lymphadenitis

Kikuchi disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dermatopathic lymphadenitis

A

Associated with a rash or other skin disease

Paracortical hyperplasia that often has associated increased Langerhans cells and macrophages containing melanin pigment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
A

Acute EBV-mediated mononucleosis

Don’t be fooled into calling this lymphoma!

Think contextually, get an EBV stain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Do reactive immunoblasts stain for CD30 and CD15?

A

They may stain for CD30, however they should NOT stain for CD15.

Thus, CD15 positivity argues for a Hodgkin lymphoma over a Hodgkinoid immunoblastic proliferation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Molecular profiling in DLBCL

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What type of DLBCL gets rituximab as part of standard therapy?

A

Activated B cell type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hans algorithm

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Myc staining in DLBCL

A

Very non-specific for the myc rearrangement – you HAVE to use FISH to detect this.

However, myc IHC is often still done as part of characterizing “double expressor lymphomas.” If a DLBCL expresses both myc >40% and BCL2 >50% by IHC, the prognosis is worse than a non-double expressor DLBCL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

“Double expressor” vs “Double hit” DLBCL

A

Double expressor = By IHC, >40% myc positive and >50% BCL2 positive. Worse prognosis than non-DE, better prognosis than double hit.

Double hit = By FISH, IGH::MYC and IGH-BCL2 rearranged. Worst prognosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stain panel for a new DLBCL diagnosis

A

Hans classifiers: CD10, BCL6, MUM1

Double expressor classifiers: MYC, BCL2

Viral infeciton classifiers: EBER ISH
(if immunocompromised, add HHV8 LANA1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Frequency of T cell antigen loss in T cell neoplasms

A

CD7 > CD5 > CD2 > CD3

17
Q

TRBC1 and TRBC2

A

Uniform expression shows clonality in T cells, similar to kappa and lambda in B cells

Two chains of the T cell beta receptor (for alpha-beta TCRs)

18
Q

Ways to interpret cytoplasmic CD3 expression

A

T-cell precursor (benign or malignant)
Aberant expression in a mature T cell neoplasm
NK-cell neoplasm

19
Q

Brentuximab vedotin

A

Anti-CD30-conjugated chemotherapy

Approved for all CD30+ T cell lymphomas AND classic Hodgkin lymphomas

For Hodgkin lymphomas, even just by morphology.

20
Q

Anti-light chain antibodies in differentiating acute EBV (mono) from classic Hodgkin lymphoma

A

Immunoblasts typically have some surface light chain expression by IHC.

If you perform anti-kappa and anti-lambda stains, you can demonstrate that the immunoblasts in mononucleosis are in fact polytypic, ruling out Hodgkin lymphoma.

21
Q

Ki-67 index is prognostic in. . .

A

Follicular and mantle cell lymphomas

22
Q

Primary cutaneous marginal zone lymphoma/LPD

A

Lymphoma in WHO5
LPD in ICC

Very indolent B cell neoplasm

23
Q

Changes in follicular lymphoma classification and grading

A
24
Q

“Testicular” FL

A

Dropped from WHO5 because it is so vanishingly rare and is not clear that it is distinct from pediatric-type FL

Still in the ICC

25
Q

Fibrin-associated LBCL

A

Do not create a mass, localized, does not invade into tissue, and may be related to local immune escape shielding EBV+ B cells from immune surveillance.

MUCH better prognosis than the rest of DLBCL-CI, hence it is now described as its own entity in WHO5.

26
Q

Looks like Primary Effusion Lymphoma, but HHV8 is negative!

A

Fluid overload-associated large B cell lymphomas in WHO5
HHV8 negative primary effusion lymphoma in ICC

Generally arise in older people with underlying medical problems who have a reason to have an effusion, with the B cell neoplasm seeming to arise secondary to the effusion. In contrast, in HHV8-associated PEL, HHV8 creates the fluid collection.

HHV8 MUST be negative.

Most lack specific immunodeficiency. More likely to involve multiple cavities than PEL. 30% of cases have HBV, which is highly associated with peritoneal involvement.

A subset of these patients go into remission after simple drainage of the fluid alone.

27
Q

Pyothorax-associated lymphoma

A

History of TB with pyothorax

Chronic suppurative inflammation

Mass is often present

28
Q

Double Hit classifications

A
29
Q

Primary diffuse large B cell lymphomas of immune privileged sites

A
30
Q

Naming for general lymphoproliferative disorders

A

Histologic Dx, Virus-association, Type of immunodeficiency if any

ex:
DLBCL, EBV+, post-transplant
DLBCL, EBV+, HIV-associated

31
Q

Plasma cell-associated paraneoplastic syndromes

A
32
Q
A

Indolent NK-cell lymphoproliferative disorder of the GI tract

Cells are immunophenotypically perfect for activated cytotoxic NK cells and show prominent perinuclear red granules

33
Q

Nodal TfH lymphomas

A